HIV (Human Immunodeficiency Virus) infects cells of the immune system and destroys or impairs their function.
Infection progressive deterioration of the immune system breaking down the body's ability to fight out infections & diseases by opportunistic bacteria, viruses and fungi.
AIDS (Acquired Immune Deficiency Syndrome) refers to the most advanced stages of HIV infection and a collection of signs and symptoms caused by more than 20 opportunistic infections or related cancers.
At the end of the session, the students shall be able to
Describe the HIV AIDS introduction, epidemiology of HIV AIDS, diagnosis of HIV AIDS, treatment of HIV AIDS and prevention control of HIV AIDS.
At the end of the session, the students shall be able to
Describe the HIV AIDS introduction, epidemiology of HIV AIDS, diagnosis of HIV AIDS, treatment of HIV AIDS and prevention control of HIV AIDS.
HIV AIDS Lecture Presented by me in my Community Dentistry Class, BIBI ASIFA DENTAL COLLEGE, SHAHEED MOHTARMA BENAZIR BHUTTO MEDICAL UNIVERSITY LARKANA, SINDH, PAKISTAN.
Viral hepatitis is the leading cause of liver cancer and the most common reason for liver transplantation
In the United States, an estimated 1.2 million Americans are living with chronic Hepatitis B and 3.2 are living with chronic Hepatitis C
Many do not know they are infected
Each year an estimated 21,000 persons become infected with Hepatitis A; 35,000 with Hepatitis B, and 17,000 with Hepatitis C
Hepatitis A – fecal/oral, contaminated food, vaccine available
Hepatitis B – blood, semen, vertical (mother-child), vaccine available
Hepatitis C – blood (IV drug use, transfusion, organ donation, unsterile injecting equipment, sexual intercourse)
Hepatitis D – survives only in cells co-infected with hepatitis B
Hepatitis E* – contaminated food or water, fecal/oral
*causes short-term disease and is not a chronic carrier state
HIV AIDS Lecture Presented by me in my Community Dentistry Class, BIBI ASIFA DENTAL COLLEGE, SHAHEED MOHTARMA BENAZIR BHUTTO MEDICAL UNIVERSITY LARKANA, SINDH, PAKISTAN.
Viral hepatitis is the leading cause of liver cancer and the most common reason for liver transplantation
In the United States, an estimated 1.2 million Americans are living with chronic Hepatitis B and 3.2 are living with chronic Hepatitis C
Many do not know they are infected
Each year an estimated 21,000 persons become infected with Hepatitis A; 35,000 with Hepatitis B, and 17,000 with Hepatitis C
Hepatitis A – fecal/oral, contaminated food, vaccine available
Hepatitis B – blood, semen, vertical (mother-child), vaccine available
Hepatitis C – blood (IV drug use, transfusion, organ donation, unsterile injecting equipment, sexual intercourse)
Hepatitis D – survives only in cells co-infected with hepatitis B
Hepatitis E* – contaminated food or water, fecal/oral
*causes short-term disease and is not a chronic carrier state
"Medical Doctors are Poor Managers". This presentation has tried to do brainstorming for them how to operate as better Health Managers. Leaders lead from the Front. Managers control from the Behind. A Doctor in a facility needs to play the role of both Leader as well as Manager.
Presentation on HIV/AIDS, public health concern- include cause, symptoms, prevention and appropriate interventions. Also it include the Epidemiological Triangle link between agent, host and environment, Status of the disease in Nepal and in world.
Buffer Stock and Safety Stock are often used interchangeably. However, this often creates confusion. Buffer Stock and Safety Stock are different from each other. Buffer stock distinguishes it from Safety stock. Buffer Stock protects the Provider from the Supplier when there is delay in receiving supply. On the other hand, the Safety Stock protects the Provider from Consumer in probabilities like an abrupt change in the demand for a particular product or uncontrollable delay in the delivery of the material from supplier
Quality of Care in a Health Facility is a major concern for Public Facilities in India. Quality Improvement Process should be driven by the Care Providers, Facility Managers and other Stakeholders integrating patient/client satisfaction and scientifically and technically sound treatment protocols.
Bottlenecks, barriers, and solutions: Results from multi-state consultations focused on reduction of childhood pneumonia and diarrhea deaths. Under-5 Malnutrition plays a great role behind deaths from Pneumonia & Diarrhoea.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
3. Fact 1 HIV (Human Immunodeficiency Virus) infects cells of the immune system and destroys or impairs their function. Infection progressive deterioration of the immune system breaking down the body's ability to fight out infections & diseases by opportunistic bacteria, viruses and fungi. AIDS (Acquired Immune Deficiency Syndrome) refers to the most advanced stages of HIV infection and a collection of signs and symptoms caused by more than 20 opportunistic infections or related cancers.
4. CD4 facts What CD4 cells do CD4 cells/T-cells/T-helper cells : Organize the immune system’s response to bacterial, fungal and viral infections. CD4 cell counts in people without HIV HIV-negative man : 400-1600/ml of blood HIV-negative women : 500-1700/ml of blood. Menstruation: Women’s CD4 cell counts go up and down during the menstrual cycle. OCP: Oral contraceptives lowers woman’s CD4 cell count. Smoking: Smokers tend to have higher CD4 cell counts (by about 140). Sleep: A lower CD4 cell count in the early morning which rises in the afternoon.
5. Fact 2Modes of transmission Vaginal, oral or anal sex withan infected person. Transfusion of infected blood. Sharing unclean needles or syringes to take drugs. Unsterilized needles for tattooing, skin piercing or acupuncture. From mother to baby in uterus during Pregnancy, childbirth (vertical transmission) or through breastfeeding. occupational exposure in health care settings.
6. Fact 3 33 million people live with HIV/AIDS worldwide, the vast majority of whom are in low & middle-income countries. An estimated 2.7 million people were newly infected with the virus in 2007.
7. Fact 4 HIV/AIDS is the world’s leading infectious killer. Claiming—to date—more than 25 million lives. 2 million people die every year from HIV/AIDS.
8. Disease Burden World Population:7124 million People Living with HIV/AIDS(PLHA): 33 million(0.46%) Sub-Saharan Africa remained the most heavily affected by HIV, accounting for 68% of all people living with HIV and for 76% of AIDS deaths 2.7 million new infections every year. India Population: 1210 million. PLHA: 2.4 million(0.19%) . India 2nd to South Africa in absolute number of HIV cases.
9. Adults and Children Estimated to Be Living with HIV, 2007(UNAIDS, 2007 @ www.unaids.org) Eastern Europe & Central Asia 1.5 million [1.1 – 1.9 million] Western & Central Europe 730 000 [580 000 – 1.0 million] North America 1.2 million [760 000 – 2.0 million] East Asia 740 000 [480 000 – 1.1 million] Middle East & North Africa 380 000 [280 000 – 510 000] Caribbean 230 000 [210 000 – 270 000] South & South-East Asia 4.2 million [3.5 – 5.3 million] Sub-Saharan Africa 22.0 million [20.5 – 23.6 million] Latin America 1.7 million [1.5 – 2.1 million] Oceania 74 000 [66 000 – 93 000] Total: 33 million (30 – 36 million)
10. Fact 5 Combination antiretroviral therapy (ART) prevents the HIV virus from multiplying in the body. If the reproduction of the HIV virus stops, then the body's immune cells are able to live longer and provide the body with protection from infections.
11. Fact 6 About 4million HIV-positive people had access to antiretroviral therapy (ART) in low- and middle-income countries in 2008. This is a 36% increase in treatment coverage compared to 2007 and a 10-fold increase over 5 years. Global coverage of ART is still low, reaching only 42% of the estimated 9.5 million people who need it.
12. Fact 7 More than 2 million children are living with HIV/AIDS, according to 2007 figures. Most of the children live in sub-Saharan Africa & were infected by their HIV-positive mothers during pregnancy, childbirth or breastfeeding. 1000 children become newly infected with HIV each day. The number of children receiving ART increased from about 75,000 in 2005 to 2,76,000 in 2008.
13. Fact 8 Mother-to-child-transmission is almost entirely avoidable,. Access to preventive interventions remains low in most developing low- & middle-income countries. However, progress has been made. In 2008, 45% of pregnant women living with HIV received anti-retroviralsto prevent mother-to-child transmission of the virus, up from 10% in 2004.
14. Fact 9 In 2007, more than 4,50,000 deaths from tuberculosis occurred among people living with HIV. This is equal to nearly a quarter of the estimated 2 million deaths from HIV in that year. Majority of people living with both HIV & TB reside in sub-Saharan Africa (about 80% of cases worldwide), of whom around 1 quarter are in South Africa.
15. Fact 10 Some key ways to prevent HIV transmission: Abstaining from high risk sex or practice safe sexual behaviors like using condoms. Getting tested & treated for sexually transmitted infections, including HIV. Avoiding injecting drugs, or if someone does, should always use new & disposable needles & syringes. Ensuring Safe Blood: Any blood or blood products that some one might need are tested for HIV.
16. Clades (viral subtypes) of HIV(Harrison’s Principles of Internal Medicine, 17th edition, 2008) HIV has genetic diversity and varies in different geographic regions HIV: 3 strains: M, N, 0 (M responsible for most infections worldwide) Main subtype in North America is subtype B Subtype C is most common worldwide AE, AG, AB are circulating recombinant forms (CRF) greatest diversity occurs in sub-Saharan Africa A key concern for AIDS vaccine researchers is the tremendous genetic diversity of HIV
17. History of the Disease: African green monkeys Haiti Carribean countries USA Whole world. 1981 Los Angeles cases of Kaposi sarcoma and P. jiroveci pneumonia in young homosexual males and IV drug abusers. 1986 Chennai- first HIV positive case 1987 Mumbai - first AIDS patient
18. Life cycle of HIV (AIDSInfo) Binding and fusion Reverse transcription Integration Transcription Assembly 6. Budding
21. Key populations at risk of HIV: Heterosexuals (developing countries) Men who have sex with men (MSM in developed countries)/Bisexuals. Injection drug users (IDU). Commercial sex workers (CSW), Migrants, Truck drivers. Newborns of infected mothers. Prisoners, transfusion recipients, professionals. Sexually transmitted infections (STI) clinic attendees. Adolescents.
33. Clinical Spectrum of HIV/AIDS Initial Infection: Acute Retroviral Syndrome Asymptomatic(2-6 weeks upto 36 weeks) 50% have symptoms of acute viral fever like- fever, rash, joint pain, sore throat, diarrhea, swollen lymph nodes. HIV antibodies: not detectable. Window Period but viral multiplication present. Patient is highly infective.
34. Clinical Spectrum of HIV/AIDS Asymptomatic Carrier State: (Clinical Stage I) Early Asymptomatic Disease(CD4 count>500/ml) & no overt signs. Progressive deterioration in immune system. Some remain Asymptomatic & don’t seek T/t(5-7 years). Signs & symptoms of Persistent GeneralisedLymphadenopathy(PGL) HIV antigen & antibodies: Both detectable. Patient is highly infective.
35. Clinical Spectrum of HIV/AIDS AIDS Related Complex(ARC) State: (Clinical Stage II) Intermediate HIV Infection(CD4 count: 200-500/ml) No Opportunistic Infection. Early signs & symptoms of Recurrent Oral Ulcers, Moderate weight loss(<10% of body weight), Recurrent RTI(Sinusitis, Pharyngitis, Tonsilitis, Otitis Media) Herpes zoster infection, Seborrhoic Dermatitis/pruritus. Herpes zoster Angular Chelitis Pulmonary tuberculosis.
36. Clinical Spectrum of HIV/AIDS AIDS State: Late Stage HIV Disease/(Clinical Stage III) Signs & symptoms of Opportunistic Infections(CD4 count: 50-200/ml) Unexplained Intermittent/Persistent fever, night sweat, Unexplained chronic diarrhoea (>1 month), Unexplained Severe weight loss(>10% of body weight) Unexplained Anemia, Leucopenia, Thrombocytopenia. Oral Hairy Leukoplakia Severe Infection(empyema, meningitis, pneumonia) OIs: Pneumocystisjeroveci pneumonia, Cerebral Toxoplasmosis, Pulmonary/disseminated Tuberculosis, Cryptococcal Meningitis/ Severe OropharyngealCandidiasis.
37. Clinical Spectrum of HIV/AIDS Advanced State of HIV/AIDS: (Clinical Stage IV) Signs of HIV wasting syndrome(CD4 count:< 50/ml) Neurological manifestations of motor abnormality, cognitive impairement, behavior changes, various types of malabsorption, wasting of muscles. Extra-Pulmonary TB/Milliary TB MAIC infection Kaposi’s Sarcoma/CNS Lymphoma Histoplasmosis OesophagealCandidiasis(Candidiasis of trachea, bronchi, lungs) Chronic cryptosporidiosis, cryptococcosis, isosporiasis.
38. Initial Evaluation of the Patient Full medical and sexual history Addiction history History of sexually transmitted diseases (STDs) History of Blood Transfusion Immunization history Previous HIV test Current state of health including assessment of clinical manifestations of infection Conditions that may interfere with HIV management (eg. heart disease) Systems review including other illnesses/ opportunistic infections Complete physical exam
39. Opportunistic Infections Associated With AIDS Categories of Opportunistic Infections or Diseases • Bacterial & Mycobacterial • Fungal • Malignancies or cancers • Protozoal • Viral • Neurological conditions
41. HIV Counseling Three time testing of blood to know the HIV status of a person. Tests are available at Integrated Counseling and Testing Center(ICTC). HIV Counseling: Pre-test & Post-test Type. Tremendous social, physical, mental implication on being +ve. Unethical to do testing without informed consent. Privacy of the patient history is maintained Adequate time is given for counseling.
42. Post-test Counseling Acceptance of sero-status. Education about risks of transmission/high risk behavior(“NO” to : donate blood, share needle, do unsafe sex, have pregnancy). Prevention of Parent-to-Child Transmission (PPCT). Plan for future orphans/wills. Early management of Opportunistic Infections. Preventive therapy like TB prophylaxis, Contraception etc. Improvement in quality of life by ART. Reference to Social Support.
43.
44. Detects viral core protein p-24 & gp-41.Rapid tests (CDC, 2008) HIV antibody alternate screening tests that produce results within ~20 minutes. FDA-approved tests that use blood or oral fluid, approved since 2002.
45.
46. FDA-Approved Rapid HIV Antibody Screening Tests CDC, 2008 OraQuick Rapid HIV-1/2 Antibody Test Reveal G3 Rapid HIV-1 Antibody Test Uni-Gold Recombigen HIV Test Multispot HIV-1/HIV-2 Rapid Test Clearview HIV 1/2 Stat Pak Clearview Complete HIV 1/2
47. Testing in Pregnancy opt-in testing, person cannot be given an HIV test unless specifically requested. opt-out testing, health care providers must inform pregnant women that an HIV test will be included in the standard group of tests pregnant women receive. A woman will receive that HIV test unless she specifically refuses. The CDC currently recommends that health care providers adopt an opt-out approach to perinatal HIV testing .
48. Prevention & Control of AIDS: Elimination of Reservoir: ART/HAART Treatment is life long but not curative but supportive. Reduce HIV-related morbidity and prolong survival. Improve quality of life & delay onset of AIDS. Restore and preserve immunological functions. Maximally suppress viral load (HIV-RNA). Prevent vertical HIV transmission. Newer regimens are potent, durable, less toxic, and have simplified regimens (simpler regimens improve adherence). Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Nucleoside Analogues.
49. Clinical Guidelines WHO: 2010 Recent guidelines support earlier treatment and recommend that a CD4 count of 350/μL is the lowest count to begin ART(WHO-2010) Symptomatic Asymptomatic CD4 < 350/μL CD4 > 350/μL Individualized treatment ● High viral load (>1,00,000 copies/mL) ● Rapid CD4 decline (>100/μL per yr) ● Hepatitis B or C coinfection ● HIV-associated nephropathy ● Risk factors for non-AIDS diseases (eg. cardiovascular disease) ART recommended
51. Challenges to Disease Management Toxicities or adverse effects. Drug interactions. Clinical manifestations related to the drugs and the HIV infection itself. Maintenance of adherence. Threat of drug resistance. Co-morbid conditions. Pregnancy.
62. Zidovudine-600 mg every day Lamivudine-150 mg twice a day Indinavir-800 mg every 8 hours Nelfinavir-750 mg three times a day Post-Exposure Prophylaxis
63. Treatment Recommendations A large number of antiretroviral drugs are now available: Nucleoside and nucleotide analogues (NRTIs) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Protease inhibitors (PIs) and boosted protease inhibitors (PI/r) CCR5 antagonists Integrase inhibitors ART for initial therapy in treatment- naïve patients (Hammer et al., 2008) Two NRTIs plus either efavirenz (NNRTI) or a ritonovir-boosted protease inhibitor (eg. lopinavir/r) ART available for patients with drug-resistant HIV Prophylaxis for some opportunistic infections: Toxo, PCP, TB, MAC
64. Medical Complications of ARThttp://aidsinfo.nih.gov/contentfiles/HIVandItsTreatment_cbrochure_en.pdf Cardiovascular disease- eg. abacavir Hyperlipidemia- increased triglycerides/cholesterol Hepatotoxicity- liver damage Hyperglycemia and diabetes Lactic acidosis Lipodystrophy Osteonecrosis, osteopenia, osteoporosis- bone disease Skin rash eg. Stevens-Johnson syndrome eg. Toxic epidermal necrolysis Pancreatitis Renal or kidney failure Bleeding events Suppression of bone marrow
65. WHO’s HIV/AIDS work for the period 2006-2010 is structured around five strategic directions:
66. Testing and Counseling: Voluntary HIV counseling and testing (VCT) Infant HIV diagnosis and family testing and counseling 2. Maximizing the health sector’s contribution to HIV prevention. 3. Accelerating the scale-up of HIV/AIDS treatment and care. 4. Strengthening decentralization and expanding health systems. 5. Investing in strategic information to guide a more effective response. 1. Enabling people to know their status through confidential HIV testing and counseling.
67. NEEDS Continuous surveillance Awareness programmes Increased health care allocations Identification of high risk groups Access to treatment for all Removal of stigma and discrimination Developing appropriate guidelines
68. The Red Ribbon Express has seven coaches equipped with educational material, primarily on HIV/AIDS, interactive touch screens and 3D models, PPTCT services in the context of RCH II, HIV-TB co-infection, an LCD projector and platform for folk performances, counseling cabins and two doctors’ cabins for providing counselling and syndromic treatment for STI and RTI cases, an office, dining area and pantry. Red Ribbon Express
73. Non-AIDS Related Complications That May Be More Common Patients With HIV Hypertension (high blood pressure) Diabetes mellitus and insulin resistance Cardiovascular disease Pulmonary hypertension (increased pressure in the pulmonary artery) Cancer Osteopenia and osteoporosis (decreased bone mineral density) Liver failure Kidney failure Peripheral neuropathy Frailty Cognitive decline and dementia
74. Conclusions HIV destroys immune function leading to immune deficiency and the development of opportunistic infections, leading to the development of AIDS There is currently no cure for AIDS and no vaccine, although with good adherence to treatment, ART can prevent progression to AIDS indefinitely (ART Cohort Collaboration, 2008) In addition to side effects from ART, HIV itself can result in non-AIDS related complications Guidelines and recommendations for HIV management by the CDC and other professional organizations exist and are routinely updated